David Cabrita

Passionate about empowering healthcare systems and professionals to deliver high-quality, cost-effective treatments, to ultimately improve patient outcomes.

[David Cabrita @DavidCabrita]

I look forward to EP Live 26 starting today!

Let me know if you're planning to attend! 👋
You can also register via https://t.co/E9OXaFKA3k

#EPLive26 - via #Whova event app
#Medtronicemployee

[David Cabrita @DavidCabrita]

Truly exciting to see the pivotal trial approved! 🚀
A major milestone for advancing VT care.
Congrats to everyone involved and looking forward to how this study can impact VT patients and @EPeeps. 👏

#Sphere9VT 🫀
#Medtronic, @AfferaEP #Medtronicemployee

[Medtronic Cardiac Ablation @MDT_EPAblation]

Medtronic received FDA approval to begin a pivotal trial evaluating the Affera™ mapping and ablation system, with updated ablation software, used with the Sphere-9™ catheter for the treatment of monomorphic ventricular tachycardia (VT).

Learn more: https://t.co/8jAL1kxnZc

[David Cabrita @DavidCabrita]

Energizing conversations at #HRS2026 around the Sphere‑9™ early feasibility study 🚀🔬
The @EPeeps community was very engaged, commenting on the insights shared! 👏🤝
#Sphere9VT🫀
#Medtronicemployee
@EPeeps_Bot

[Medtronic Cardiac @MDT_Cardiac]

Redefining VT ablation.
Late-breaking clinical trial data presented at #HRS2026: Six-month results from the Sphere-9™ VT Early Feasibility Study.

Product usage represented may not be approved or cleared in all markets.

Learn more: https://t.co/ZwKyaRYd4e

#Sphere9 #Affera

[David Cabrita @DavidCabrita]

🚀 Joining @EPeeps at #HRS2026 to learn about the results of the Sphere‑9™ VT Early Feasibility Study.
🎙️ Late‑breaking session | Apr 25 | 11:00 AM | Room S100AB
Excited to engage with the EP community! #Sphere9VT🫀 #MedtronicEmployee @EPeeps_Bot

[Medtronic Cardiac @MDT_Cardiac]

Coming soon: late-breaking clinical trial data for the Sphere-9™ VT Early Feasibility Study at HRS.

Learn more: https://t.co/B78eaXcbtj

[David Cabrita @DavidCabrita]

I’m looking forward to the late-breaking Clinical Trail session on Ventricular Ablation sharing the early US experience with the lattice-tip catheter for VT ablation at #HRS2026
#Sphere9VT🫀
#Medtronicemployee

[Pasquale Santangeli @Dr_Santangeli]

Join us at #HRS2026 for the Late-Breaking Clinical Trial session on Ventricular Tachycardia Ablation.

Early U.S. experience with the dual-energy lattice-tip catheter for VT ablation - efficacy and safety data.

Sun Apr 26, 9:00 AM CT | Room S100C, McCormick Place​​​​​​​​​​​​​​​​ @CleClinicHVTI @LuigiDiBiaseMD @JagSinghMD @Osama_Dasa

[Pasquale Santangeli @Dr_Santangeli]

Join us at #HRS2026 for the Late-Breaking Clinical Trial session on Ventricular Tachycardia Ablation.

Early U.S. experience with the dual-energy lattice-tip catheter for VT ablation - efficacy and safety data.

Sun Apr 26, 9:00 AM CT | Room S100C, McCormick Place​​​​​​​​​​​​​​​​ @CleClinicHVTI @LuigiDiBiaseMD @JagSinghMD @Osama_Dasa

[Medtronic Cardiac @MDT_Cardiac]

Mark your calendars—four Medtronic educational programs featuring the cardiac ablation portfolio are coming to #HRS2026. Agenda: https://t.co/B78eaXcbtj

[David Cabrita @DavidCabrita]

✨ Looking back at what it felt like for Dr. @AndreasMetzner7 to disrupt with @AfferaEP using #Sphere9!

🗺️ Re-living “ultra-fast high-density mapping”, “beautiful sharp signals”, and “effective lesions” ⚡🔥

Something many @EPeeps relate to.
#Sphere9VT 🫀
#medtronicemployee

[Andreas Metzner @AndreasMetzner7]

👉Next step #Affera and #Sphere9: VT ablation in ischemic cardiomyopathy. Ultra-fast high density LV map, beautiful sharp signals, large and effective lesions. More to come @EPHHEppendorf.👈 @AndreasRillig @laura_rottner @AGEP_DGK @JObergassel @Phiso_de @chris_sohns

[David Cabrita @DavidCabrita]

Great initiative from #EHRA_ESC 🫀for @EPeeps_Bot @EPeeps 🩺 to share how success in catheter ablation for VT should be measured. ⚖️

🔗https://t.co/RMooLowd2H

👉 Don’t miss the chance to join the conversation and shape the future of VT ablation!
I look forward to the results!

[EHRAPresident @EHRAPresident]

🚨 New #EHRA_ESC Survey Alert! 🚨

How should we measure success in catheter ablation for ventricular tachycardia (VT)?

The #EHRA_ESC Scientific Initiatives Committee wants to hear from YOU! 🫀✨

🔗https://t.co/bB2vkKjzM9

This important survey aims to:
🔹 Identify the key outcomes that every VT ablation trial should report
🔹 Build a standardised framework for outcome reporting
🔹 Complement existing recommendations and shape the future of VT clinical research

Your input will directly help harmonise clinical trials and improve patient care worldwide 🌍💙

👉 Don’t miss the chance to contribute – join the conversation and shape the future of VT ablation!

@jongichun @Deepti_RG @escardio

[David Cabrita @DavidCabrita]

Preliminary Sphere-9 VT EFS results were shared at @VTSymposium.
✅ 100% acute procedural success
➡️ RF + PF used in 95% of cases
Learn more: https://t.co/SmQuifwL6c

@EPeeps_Bot @EPeeps @AfferaEP #PFA #Medtronicemployee @Medtronic

[Medtronic Cardiac Ablation @MDT_EPAblation]

Late-breaking data presented at VT Symposium: Acute results from the Sphere-9 VT Early Feasibility Study.

The Affera™ mapping & ablation system & Sphere-9™ catheter are not approved for treatment of ventricular arrhythmias in any geography.
Learn more: https://t.co/AhQFvO0E9g

[David Cabrita @DavidCabrita]

Can’t wait to see the results presented!
Congratulations to the #EPeeps involved!
Looking forward to how #Affera and #PFA may further impact VT patient’s lives in the future! 👏🔥 #Medtronicemployee #Electrophysiology
#VTSymposium2025

[Medtronic Cardiac Ablation @MDT_EPAblation]

Coming soon: late-breaking clinical trial data for the Sphere-9 VT Early Feasibility Study at VT Symposium. The Affera™ mapping & ablation system & Sphere-9™ catheter are not approved for treatment of ventricular arrhythmias in any geography.

[David Cabrita @DavidCabrita]

I look forward to meeting all #Epeeps at the Stanford Biodesign and #HRS2025 events!
Looking forward to reconnecting with old friends and learning from the best in the EP community.
See you there!
#Electrophysiology #MedTech #Innovation #CardiacAblation #Medtronicemployee

[Timothy Markman @Dr_Markman]

Headed to San Diego for the Stanford Biodesign New Arrhythmia Technologies Retreat! Looking forward to discussing our work to develop novel sympathetic modulation technologies - Perfect start to #HRS2025. #EPeeps https://t.co/fb0pRq78yL

[David Cabrita @DavidCabrita]

I look forward to seeing this @AfferaEP live in a box case at #EHRA2025.
Congratulations to Dr. @AndreaSarkozy and the entire @HeartBrussels team at @UZBrussel!

https://t.co/sPLoTvAR4C

#Medtronicemployee

[Ioannis Doundoulakis @IDoundoulakis]

Excited about our #sphere9 case with test pulse!
Join us at #EHRA2025 in Vienna (Live in the Box/Room 2/1st of April 08:30) where we’ll unveil exciting advancements in redo AF ablation beyond PVI. Don’t miss it!
Affera case with prof @AndreaSarkozy
@LuigipannoneM @dogi84md

[David Cabrita @DavidCabrita]

@IDoundoulakis @AndreaSarkozy @LuigipannoneM @dogi84md I look forward to seeing this @AfferaEP live in a box case at #EHRA2025. Congratulations to the entire @HeartBrussels team at @UZBrussel!
#Medtronicemployee

[David Cabrita @DavidCabrita]

Exciting news for #atrialfibrilation patients!
Hopefully this higher PVI durability will result in lower repeat ablation cases with #PFA technologies.
#Medtronicemployee

[Medtronic Cardiac Ablation @MDT_EPAblation]

Two PFA durability studies show reproducible results with the PulseSelect™ PFA system. Learn more: https://t.co/yCoEDC2shg See risk info: https://t.co/6QBPyI3OyK

[EHRAPresident @EHRAPresident]

🚨 #EHRA_ESC Survey on VT Management: Key Takeaways!

🏥 VT ablation is mainly done in university hospitals, with on-site cardiac surgery

🩻 CMR/LGE-CMR is routinely used before ablation in 50%+ of cases.

⚡ No centers perform prophylactic VT ablation

📍 85% use HD mapping catheters, but advanced ablation techniques remain scarce

🧬 EPS/genetic testing is mainly for younger symptomatic patients with structural heart disease

Find out more 👉https://t.co/ricOaYNd8y

[David Cabrita @DavidCabrita]

Interesting article for @EPeeps_Bot.
For Dr. Anthony Moretta, “A great feature of both the #PulseSelect catheter and @AfferaEP #Sphere9 catheter is their precision”. “I thought it (#PulseSelect) was the most precise single-shot catheter”.
⬇️See more below ⬇️👀
#Medtronicemployee

[EP Lab Digest @EPLabDigest]

There Is a Place for Both Single-Shot and Focal Pulsed Field Ablation Practice:
@EPLabDigest sat down with Anthony Moretta, MD, to discuss his experience with the @Medtronic PulseSelect™ PFA System and Sphere-9™ catheter.
📖https://t.co/n6ynhajTRu

[Medtronic Cardiac Ablation @MDT_EPAblation]

Register to attend the 2025 Cardiac Ablation Summit with Program Directors Dr. Devi Nair and Dr. Suneet Mittal to hear the latest in all things ablation. #Epeeps #CardiacAblationSummit Link: https://t.co/RjrqP6uI8D

[David Cabrita @DavidCabrita]

#medtronicemployee

[Julian Chun @jongichun]

Important international collaboration to better understand this serious complication- supported by EHRA SIC!.

[David Cabrita @DavidCabrita]

#Medtronicemployee

[David Cabrita @DavidCabrita]

Just published! How many more applications would #Epeeps have to do with #PulseSelect to reach the same level of #Hemolysis reported by the Pentaspline #PFA catheter? 🤔 At least 4x more! https://t.co/AO9WKQeuTO #MedtronicEmployee https://t.co/OOetI1mZUB